CytomX Therapeutics, Inc. Common Stock (CTMX) Stock
NASDAQ · CTMX
2.69
Fundamentals
Market cap
$588.33M
Price / Earnings ratio
-7.2x
Price / Sales ratio
32.7x
Price / Book ratio
2.0x
Return on assets
-29.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
CytomX Therapeutics Q2 Earnings Call Highlights
NeutralCTMXAugust 7, 2026
MarketBeatNeutral
CytomX Therapeutics Q2 Earnings Call Highlights
CTMX

Zacks Investment Research
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
NeutralCTMXAugust 7, 2026
Zacks Investment ResearchNeutral
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CTMX

Zacks Investment Research
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
NeutralCTMXJuly 8, 2026
Zacks Investment ResearchNeutral
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CTMX

Zacks Investment Research
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
NeutralCTMXMay 8, 2026
Zacks Investment ResearchNeutral
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CTMX
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
91M60M30M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
182M120M60M0
Revenue to Profit
2025$76.2M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-20.4M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
CytomX Therapeutics Q2 Earnings Call Highlights
NeutralCTMXAugust 7, 2026
MarketBeatNeutral
CytomX Therapeutics Q2 Earnings Call Highlights
CTMX

Zacks Investment Research
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
NeutralCTMXAugust 7, 2026
Zacks Investment ResearchNeutral
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CTMX

Zacks Investment Research
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
NeutralCTMXJuly 8, 2026
Zacks Investment ResearchNeutral
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CTMX

Zacks Investment Research
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
NeutralCTMXMay 8, 2026
Zacks Investment ResearchNeutral
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
CTMX

Stocktwits
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside
NeutralCTMXMarch 18, 2026
StocktwitsNeutral
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside
CTMX

Zacks Investment Research
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
NeutralCTMXMarch 17, 2026
Zacks Investment ResearchNeutral
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CTMX

Stocktwits
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls
NeutralCTMXMarch 17, 2026
StocktwitsNeutral
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls
CTMX

The Motley Fool
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
NeutralCTMXMarch 16, 2026
The Motley FoolNeutral
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
CTMX

Zacks Investment Research
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
NeutralCTMXMarch 16, 2026
Zacks Investment ResearchNeutral
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
CTMX

Stocktwits
Why CTMX Stock Is Soaring 54% Pre-Market Today?
NeutralCTMXMarch 16, 2026
StocktwitsNeutral
Why CTMX Stock Is Soaring 54% Pre-Market Today?
CTMX
About CytomX Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees69
CEODr. Sean A. McCarthy DPHIL
IPO DateOct 8, 2015
HeadquartersSouth San Francisco, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Sean A. McCarthy DPHIL | Chairman & CEO | 1967 |
| Mr. Christopher W. Ogden | SVP, CFO & Secretary | 1984 |
| Ms. Rachael Lester | Chief Business Officer & Senior VP | 1978 |
| Dr. Marcia P. Belvin Ph.D. | Senior VP & Chief Scientific Officer | 1967 |
| Ms. Alejandra Veronica Carvajal J.D. | Chief Legal Officer | 1974 |
| Ms. Danielle Olander-Moghadassian | Senior VP & Chief Human Resources Officer | — |
| Ms. Leslie Robbins J.D. | Senior Vice President of Intellectual Property | — |
| Dr. Yu-Waye Chu M.D. | Senior VP & Chief Medical Officer | 1968 |
| Ms. Dawn Benson | Senior Vice President of Quality & Product Manufacturing | — |
| Dr. Stephanie Robertson Ph.D. | Senior Vice President of Alliances & Program Leadership | — |
Fundamentals
Valuation
Market cap$588.33M
Price-to-sales ratio32.74
Price-to-book value1.98
Price-earnings ratio-7.20
Return on Equity-39.00%
Return on Sales-166.00%
Return on Assets-29.00%
PEG ratio-1.80
Earnings Per Share
Earnings Per Share$-0.50
Income Statement
Average volume4,296,562
EBITDA$-53.13M
1 year high (52w)$8.21
1 year low (52w)$2.33
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$12.50
Est return
362.96%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.2 | +16.0 | +16.4 | -35.4 | ||||||||
| 2022 | +2.4 | -18.2 | -24.6 | -39.1 | -11.5 | +18.1 | -22.3 | +5.6 | -4.0 | -12.1 | +32.8 | -6.4 |
| 2023 | +67.7 | -19.8 | -30.4 | +5.8 | -0.6 | +2.4 | -2.2 | -11.2 | -14.0 | -12.0 | +28.7 | +9.9 |
| 2024 | -9.5 | +60.1 | -17.7 | -24.2 | -66.9 | -30.3 | +3.8 | -11.9 | +5.4 | -13.0 | +1.0 | -5.5 |
| 2025 | -19.8 | -19.0 | -1.5 | +27.6 | +248.7 | -9.6 | -7.2 | -13.2 | +53.4 | +6.6 | +8.9 | -0.7 |
| 2026 | +33.9 | -11.8 | -12.0 | -7.5 | -13.9 | +8.7 | -13.9 | +6.0 | -26.4 |



